Abstract

BackgroundThe discovery of a fetal cells transfer to the mother is a phenomenon with multiple implications for autoimmunity and tolerance. The prevalence and meaning of the feto-maternal microchimerism (MC) in rheumatic diseases has not been thoroughly investigated. The aim of this study was to analyze the prevalence of fetal MC in patients with inflammatory rheumatic diseases and to investigate the association of MC with disease onset and current status.MethodsA total of 142 women who gave birth to at least one male offspring were recruited: 72 women with rheumatoid arthritis (RA), 16 women with systemic lupus erythematosus (SLE), and 54 healthy women. For the detection of fetal microchimerism a nested PCR method was used to amplify a Y chromosome specific sequence (TSPY1). For characterization of disease activity we analyzed autoantibody profiles and X-rays in RA, and in addition complement levels in SLE respectively.ResultsA significant higher prevalence of fetal MC was found in RA (18%) and SLE (31%) compared to controls (3.7%) (p = 0.02 and p = 0.006, resp.). The mean age at disease onset was comparable in MC + and MC- RA patients. Disease onset occurred 18.7 (MC +) and 19.8 (MC-) years post partum of the first son, respectively. The presence of anti-CCP and RF did not differ significantly, anti-CCP were found in 75% of MC + and 87% of MC- patients, RF in 75% of both MC + and MC- patients. A slightly higher mean Steinbrocker score in MC + patients was associated with longer disease duration in MC + compared to MC- RA. In SLE patients the mean age at disease onset was 42.6 years in MC + and 49.1 years in MC- patients. Disease onset occurred 24.0 and 26.4 years post partum of the first son for MC + and MC- patients, respectively. The presence of ANA and anti-dsDNA antibodies, C3, C4 and CH50 did not differ significantly.ConclusionOur results indicate a higher frequency of long-term male MC in RA and SLE patients compared with controls without impact on disease onset and status in RA and SLE.

Highlights

  • The discovery of a fetal cells transfer to the mother is a phenomenon with multiple implications for autoimmunity and tolerance

  • The overall prevalence of fetal MC was 18.1% in Rheumatoid arthritis (RA) patients and 31.3% in patients with systemic lupus erythematosus (SLE) which is significantly higher as compared to 3.7% in healthy controls (HC) (p = 0.023 and p = 0.006, resp.) (Table 1)

  • The mean age at the birth of the first son was 25.9 years which is comparable to the RA and SLE patients

Read more

Summary

Introduction

The discovery of a fetal cells transfer to the mother is a phenomenon with multiple implications for autoimmunity and tolerance. The prevalence and meaning of the feto-maternal microchimerism (MC) in rheumatic diseases has not been thoroughly investigated. The aim of this study was to analyze the prevalence of fetal MC in patients with inflammatory rheumatic diseases and to investigate the association of MC with disease onset and current status. Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are autoimmune diseases with a higher prevalence in women than in men (3:1 women vs men in RA and 9:1 in SLE, respectively) [1]. In the field of rheumatic diseases patients with scleroderma, RA, SLE und Sjögren’s syndrome have been investigated [9,10,11,12,13,14,15,16]. Data are inconsistent due to small numbers of patients, different methodology, and patient selection

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call